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1. Introduction
An ideal drug delivery system fulfils the objective of maximizing therapeutic effect while
minimizing toxicity.  With the progress in time and advances in science and technology,
dosage forms have evolved from simple mixtures and pills, to highly sophisticated systems,
which are known as novel drug delivery systems. Nanoemulsions are novel drug deliv‐
ery systems consisting of emulsified oil and water systems with mean droplet diameters
ranging from 50 to 1000 nm. Usually, the average droplet size is between 100 and 500 nm
and can exist as oil-in-water (o/w) or water-in-oil (w/o) form, where the core of the particle
is either oil or water, respectively. Nanoemulsions (Figs. 1 and 2) are made from pharma‐
ceutical  surfactants that  are generally regarded as safe (GRAS).  The surfactant type and
concentration in the aqueous phase are  chosen to  provide good stability  against  coales‐
cence. Several types of oils-natural semi-synthetic and synthetic are used in the formula‐
tion of nanoemulsions. The capacity of nanoemulsions to dissolve large quantities of low
soluble drugs along with their mutual compatibility and ability to protect the drugs from
hydrolysis and enzymatic degradation make them ideal drug delivery vectors [1]. The major
advantages  of  nanoemulsions  as  drug  delivery  carriers  include  increased  drug  loading,
enhanced drug solubility and bioavailability, reduced patient variability,  controlled drug
release, and protection from enzymatic degradation [2].
A lot of techniques are available for enhancing absorption of poorly water-soluble drugs, like
use of lipid-based systems. Thus enhancement of aqueous solubility in such case is a valuable
goal to successfully formulate them into bioavailable dosage forms. A range of novel strategies
are currently being developed for efficient delivery of poorly water-soluble drugs, such as the
formulation of amorphous solid form, nanoparticles, microemulsions, solid dispersions, melt
extrusion, salt formation and formation of water-soluble complexes. Among all, the most
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Nanoemulsions courtesy of the Chemical, Materials and Surfaces unit at SP Technical Research Institute of Sweden
(former YKI, Institute for Surface Chemistry). Obtained via: http://www.vironova.com/nanoemulsions-casebody. Ac‐
cessed on April 27, 2014.
Figure 1. A silicate particle-stabilized oil in water nanoemulsion imaged using negative stain TEM (left panel) and cryo
TEM (right panel).
Figure 2. Negative stain TEM image of a silicate particle-stabilized oil in water nanoemulsion. Obtained via: http://
www.vironova.com/nanoemulsions-casebody. Accessed on April 27, 2014.
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accepted approach is the lipid-based formulation approach [3,4]. Lipid-based formulations
enhance the absorption by enhancing solubilization, prolonging gastric residence time,
stimulating the intestinal lymphatic transport pathway, altering intestinal permeability,
reduced activity of efflux transporters and reduced metabolism. Lipid-based formulations
present a large range of optional systems such as solutions, suspensions, self-emulsifying
systems and nanoemulsions.
Nanoemulsions can be prepared by high- and low-energy methods. Both high-energy and low-
energy methods can produce stable nanoemulsions. High-pressure homogenizer or ultra‐
sound generator can be used for the preparation of nanoemulsion by high-energy
emulsification method. Self emulsification and phase inversion methods-phase inversion
temperature and phase inversion composition are low-energy methods for the preparation of
nanoemulsions. Low-energy emulsification methods depend on the phase behaviour and
properties of the constituents, and they utilize the stored energy of the system to form nano
droplets. The emulsification can be brought about by changing the parameters such as
temperature and composition, which would affect the hydrophilic lipophilic balance of the
system.
This chapter focused on recent advances in the formulation, characterization and application
of nanoemulsions in drug delivery. Nanoemulsion can be formulated for delivery of drugs
through various routes. Nanoemulsions are well tolerated orally and on the skin and mucous
membranes when used to deliver topically active drugs. As a result they are used as vehicles
for drugs active against herpes labialis, fungal infections, bacterial infections, vaginitis, etc.
Nanoemulsion globules can fuse with membranes of lipid-containing organisms facilitating
penetration and transfer. Less amount of surfactant is required in nanoemulsions compared
to other emulsion systems. This can increase the bioavailability of poorly soluble drugs since
small particles easily cross the absorption membrane. Furthermore, very small size provides
large surface area which eases the solubilization and penetration through the skin or epithelial
layer [5].
2. Nanoemulsion based delivery system: types and properties
2.1. Self emulsifying formulations (SEFs)
Self-emulsifying formulations (SEFs) are mixtures of oil, surfactant, co-surfactant, and co-
solvents (absence of external phase water) and forms a transparent isotropic solution, which
emulsify under gentle agitation similar to those which would be encountered in gastro
intestinal tract (GIT). It has been recognized that this formulation when administered orally
undergo spontaneous emulsification in aqueous GI fluids [6]. This emulsified oil (triglycerides)
stimulates bile secretion and drug containing oil droplets are further emulsified by bile salts.
Lipid droplets are then metabolized by lipases and co lipases, secreted from the salivary gland,
gastric mucosa and pancreas, which also hydrolyze the triglycerides into di-and monoglycer‐
ides and free fatty acids. Further, solubilization of these molecules occurs during the passage
through the GI tract and eventually forms a range of emulsion droplets, vesicular structures
Nanoemulsions — Advances in Formulation, Characterization and Applications in Drug Delivery
http://dx.doi.org/10.5772/15371
79
and mixed micelles containing bile salts, phospholipids and cholesterol [6]. Upon mixing with
water the system SEFs have an ability to form fine colloidal droplets with very high surface
area. In many cases, this accelerates the digestion of the lipid formulation, improves absorp‐
tion, and reduces food effect and inter-subject variability [7]. Self emulsifying formulations
distribute readily in the GI tract, the digestive motility of the stomach and the intestines
provides sufficient agitation enough for the spontaneous formation of emulsions [8,9].
SEFs prepared using surfactants of HLB < 12 possess high stability and improved dissolution
(for poorly soluble drugs) due to enhancement in surface area on dispersion [6]. Therefore,
their absorption is independent of bile secretion and ensures a rapid transport of poorly soluble
drugs into the blood [6].
According to Reiss [10], self emulsification occurs when the entropy changes that favor
dispersion is greater than the energy required to increase the surface area of the dispersion [10].
The free energy of the conventional emulsion is a direct function of the energy required to
create a new surface between the oil and water phase and can be described by the equation:
2Δ 4i iG N rp s=å (1)
where, ΔG is the free energy associated with the process, ri is the radius of droplets, Ni is the
number of droplets, σ is the interfacial energy [11]. The two phases of the emulsion tend to
separate with time to reduce the interfacial area and thus, minimize the free energy of the
system(s). The conventional emulsifying agents stabilize emulsions resulting from aqueous
dilution by forming a monolayer around the emulsion droplets, reducing the interfacial energy
and forming a barrier to coalescence. On the other hand, emulsification occurs spontaneously
with SEDDS, as the free energy required to form the emulsion is low, whether positive or
negative [12]. For emulsification to take place, it is vital for the interfacial structure to offer
negligible or no resistance against surface shearing [13]. The ease of emulsification has been
suggested to be related to the ease of water penetration into various liquid crystals or gel phases
formed on the surface of the droplet [14-16]. The interface between the oil and aqueous
continuous phases is formed upon addition of a binary mixture (oil/non-ionic surfactant) to
water [14]. This is followed by solubilization within the oil phase, as a result of aqueous
penetration through the interface. Invariably, this tends to occur until the solubilization limit
is attained close to the interphase. Further, aqueous penetration will lead to the formation of
the dispersed liquid crystal phase. Ultimately, everything that is in close proximity with the
interface will be liquid crystal, the actual amount of which depends upon the emulsifier
concentration in the binary mixture. Hence, following gentle agitation of the self-emulsifying
system, water rapidly penetrates into the aqueous cores leading to interface disruption and
droplet formation [16].
When compared with emulsions, which are sensitive and metastable dispersed forms, SEFs
are physically stable formulations that are easy to manufacture. Thus, for lipophilic drugs that
exhibit dissolution rate-limited absorption, these systems may offer an improvement in the
rate and extent of absorption and result in more reproducible blood time profiles [17]. SEFs
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have been transformed into solid dosage forms using techniques such as melt granulation,
where the lipid excipient acts as a binder and solid granules are produced on cooling. Solvents
or supercritical fluids can be used with semisolid excipients, which are solubilized and then
the solvent evaporated to produce a waxy powder. Spraying techniques can be used to produce
powder formulations. These techniques enable the production of granules or powders that can
then be compressed into a tablet form or filled into capsules. In all cases, the lipid excipients
used must be semi‐solid at room temperature [18].
2.1.1. Self emulsifying drug delivery systems (SEDDS)
Self-emulsifying drug delivery system (SEDDS) is a strategy that has drawn wide research
interest, basically due to its distinct capacity to solubilize and improve the bioavailability of
hydrophobic drugs. This it does by ensuring aqueous solubility of the lipophilic drug [19]. The
presence of oil makes SEDDS unique and distinguishes them from ordinary surfactant
dispersions of drugs [20]. SEDDS are isotropic combination of drug, lipid/oil, cosolvents and
surfactants [19]. On dilution by an aqueous phase they form fine stable oil-in-water (o/w)
emulsions or fine lipid droplets which is the characteristic feature of these systems. When such
a formulation is released into the lumen of the GIT, it disperses to form a fine emulsion
generally o/w emulsion. SEDDS are generally formulated with triglyceride oils and ethoxy‐
lated nonionic surfactants. In general, the concentration of surfactant is greater than 25% in
the formulation. The size of droplets ranges approximately less than 100 nm [19].
SEDDS are believed to be superior compared with lipid solutions due to the presence of
surfactants in the formulations leading to a more uniform and reproducible bioavailability [7].
Advantages of SEDDS include more consistent drug absorption, selective targeting of drug(s)
toward specific absorption window in GIT, protection of drug(s) from the gut environment,
control of delivery profiles, reduced variability including food effects, enhanced oral bioa‐
vailability enabling reduction in dose and high drug loading efficiency [21]. Self emulsifying
formulations spread readily in the gastrointestinal tract (GIT), and the digestive motility of the
stomach and intestine provide the agitation necessary for self emulsification. These systems
advantageously present the drug in dissolved form and the small droplet size provides a large
interfacial area for the drug absorption. SEDDSs typically produce emulsions with turbid
appearance, and droplet size between 200 nm to 5 μm while self micro emulsifying drug
delivery systems (SMEDDSs) form translucent micro-emulsions with droplet size of less than
200 nm. However, self nano emulsifying drug delivery systems (SNEDDS) produces clear or
transparent emulsion with droplets size less than 100 nm [22,23]. When compared with
emulsions, which are sensitive and metastable dispersed forms, SEFs are physically stable
formulations that are easy to manufacture. Thus, for lipophilic drug compounds that exhibit
dissolution rate-limited absorption, these systems may offer an improvement in the rate and
extent of absorption and result in more reproducible blood time profiles [17]. SEDDS are
prepared in two forms: Liquid and solid SEDDS (S-SEDDS). S-SEDDS are prepared by
solidification of liquid self-emulsifying components into powder. This powder is then used to
produce various solid dosage forms, for example self-emulsifying pellets, self-emulsifying
tablets etc [19]. S-SEDDS do not suffer with the problems like liquid SEDDS (L-SEDDS). It has
Nanoemulsions — Advances in Formulation, Characterization and Applications in Drug Delivery
http://dx.doi.org/10.5772/15371
81
the advantages like low manufacturing cost, more stability and is more patient compliance,
because they are available as solid dosage form in tablets or pellet form. In many studies it
have been reported that SEDDS are used for delivering and targeting hydrophobic drugs such
as coenzyme Q10, halofantrine, vitamin E and cyclosporine-A [19]. The solid SEDDS focus on
the incorporation of liquid/semisolid ingredients into powders employing diverse solidifica‐
tion techniques like spray drying, melt granulation, moulding, melt extrusion, and nanopar‐
ticle technology. The powders can then be formulated as solid dosage forms like self-
emulsifying tablets and self-emulsifying pellets [16]. Alternative approaches for the
development of solid SEDDS comprise adsorption by solid carriers like microcrystalline
cellulose, colloidal silica and various viscosity grades of HPMC, and use of high melting point
solid excipients like Lutrol® and Gelucire® [16]. The idea of blending the potential SEDDS with
that of the pellets through the inclusion of a self-emulsifying mixture into microcrystalline
cellulose, and the production of pellets using extrusion-spheronization was first introduced
by Newton et al [24].
High levels of surfactant typically present in SEDDS formulations can invariably lead to severe
GI side-effects. Hence, a new class of SEDDS formulations, i.e., supersaturable SEDDS (S-
SEDDS) has been designed to reduce the amount of surfactant by incorporating a water soluble
polymeric precipitation inhibitor (PPI) [25] Such formulations have been developed specifi‐
cally to reduce the surfactant side-effects and achieve rapid absorption of poorly soluble drugs
[16]. The system is intended to generate and maintain a metastable supersaturated state in
vivo by preventing or minimizing the precipitation of the drug through the use of a suitable
PPI. Supersaturation is intended to increase the thermodynamic activity of the drug beyond
its solubility limit, and therefore, to result in an increased driving force for transit into and
across the biological barrier [26]. The S-SEDDS formulations have been demonstrated to
improve both the rate and extent of the oral absorption of poorly water-soluble drugs quite
effectively [25, 27, 28]. The inclusion of cellulosic polymers in the S-SEDDS formulation tends
to effectively suppress the precipitation of drugs [29]. Various viscosity grades of hydroxy‐
propyl methylcellulose (HPMC) are well-recognized for their ability to inhibit crystallization
and, thereby, generate and maintain their supersaturated state for extended time periods [16].
In vitro dilution of the S-SEDDS formulation results in the formation of a microemulsion,
followed by slow crystallization of the drug on standing indicating that the supersaturated
state of the system is prolonged by HPMC in the formulations. In the absence of HPMC, the
SEDDS formulation undergoes rapid precipitation, yielding a lower drug concentration [25].
The significantly reduced amount of surfactant used in the S-SEDDS formulation approach
significantly reduces toxicity and improves safety profile over the conventional SEDDS
formulations [16].
Positively  charged  SEDDS  have  also  been  produced;  many  physiological  studies  have
proved that the apical potential of absorptive cells, as well as that of all other cells in the
body, is  negatively charged with respect to the mucosal solution in the lumen [16].  The
drug exposure of the positively charged SEDDS has been found to be higher as well as the
conventional formulations especially for bioavailability enhancement.  The binding of the
cationic SEDDS has been found to be much higher compared with the anionically charg‐
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ed formulation,  suggesting increased adhesion of  the droplets  to the cell  surface due to
electrostatic attraction [16].
Different dosage forms of S-SEDDS include the dry emulsions, self-emulsifying capsules, self-
emulsifying sustained/controlled-release tablets, self-emulsifying sustained/controlled-
release pellets, self-emulsifying solid dispersions, self-emulsifying beads, self-emulsifying
sustained-release microspheres, self-emulsifying nanoparticles, self-emulsifying supposito‐
ries and self-emulsifying implant [29 – 34].
2.1.1.1. Advantages of SEDDS
SEDDS possess the following advantages among others [11]:
• Improvement and reduction in the variability of GI absorption of poorly water soluble,
lipophilic drugs.
• Possible reduction in, or elimination of, a number of development and processing steps (e.g.,
salt selection or identification of a stable crystalline form of the drug, coating, taste masking,
and reduced need for containment and clean-up requirements during manufacture of
highly-potent or cytotoxic drug products).
• Food does not interfere with the absorption of drug by use of such systems.
• Relative ease of manufacture using readily available equipment.
• The dose ranging from less than 25 mg to greater than 2000 mg can be administered by using
these systems.
• These systems enhance oral bioavailability due to bypass of hepatic metabolism and delivers
drug directly into systemic circulation.
• Inhibition of p-glycoprotein mediated drug efflux and pre-absorptive metabolism by gut
membrane bound cytochrome enzyme.
• Protection of sensitive drug substances
• High drug payloads.
• Liquid or solid dosage forms.
• Reduced energy requirement for emulsion formation.
• Control of delivery profile
• Promotion of lymphatic drug transport.
• They enhance absorption of lipophilic drugs by stimulating pancreatic and biliary secretions
and by prolongation of gastric residence time.
2.1.1.2. Disadvantages of SEDDS
Disadvantages of SEDDS include [11, 35]:
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• Lack of good predicative in vitro models for assessment of the formulations.
• Traditional dissolution methods do not work, because formulations are independent on
digestion prior to release of the drug.
• In vitro model needs further development and validation.
• Different prototype lipid based formulations needs to be developed and tested in vivo.
• Chemical instabilities of drugs and high surfactant concentrations in formulations (approx‐
imately 30-60%) may irritate GIT.
• Volatile co solvents may migrate into the shells of soft or hard gelatin capsules, resulting in
the precipitation of the lipophilic drugs.
• The precipitation tendency of the drug on dilution may be higher due to the dilution effect
of the hydrophilic solvent.
• Formulations containing several components become more challenging to validation.
2.1.2. Self nano emulsifying drug delivery systems (SNEDDSs)
Self-nano emulsifying drug delivery systems (SNEDDS) are isotropic mixtures of oil, surfac‐
tant, co-surfactant and drug that form fine oil-in-water nanoemulsion when introduced into
aqueous phases under gentle agitation. SNEDDS spread readily in the gastrointestinal tract,
and the digestive motility of the stomach and the intestine provide the agitation necessary for
self-emulsification [36]. SEDDSs typically produce emulsions with turbid appearance, and
droplet size between 200 nm to 5 μm, while self micro emulsifying drug delivery systems
(SMEDDSs) form translucent micro-emulsions with droplet size of less than 200 nm. However,
self nano-emulsifying drug delivery systems (SNEDDS) produce clear or transparent emulsion
with droplets size less than 100 nm [22, 23].
Successful formulation of SNEDDS depends on the thorough understanding of the spontane‐
ous nano-emulsification process and also on the physicochemical and biological properties of
the components used for the fabrication of SNEDDS. The factors influencing the phenomenon
of self nano-emulsification are:
• The physicochemical nature and concentration of oily phase, surfactant and co-emulsifier
or co surfactant or solubilizer (if included)
• The ratio of the components, especially oil-surfactant ratio
• The temperature and pH of the aqueous phase where nano-emulsification would occur
• Physicochemical properties of the drug, such as hydrophilicity/lipophilicity, pKa and
polarity.
These factors should receive attention while formulating SNEDDS. In addition, the accepta‐
bility of the SNEDDS components for the desired route of administration is also very important
while formulating SNEDDS [36].
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SNEDDS offer a reduction in bioavailability and can offer reproducibility in plasma profiles
of drugs. The ability of the SNEDDS in improving Cmax and oral bioavailability or therapeutic
effect has been established for various hydrophobic drugs. The improvement in bioavailability
can be translated into reduction in the drug dose and dose-related side effects of many
hydrophobic drugs, such as antihypertensive and antidiabetic drugs [37]. Transretinol acetate
SNEDDS emulsion, anti hyperlipidemic, probucol, estrogen receptor antagonist, tamoxifen
citrate, calcium channel blocker, felodipine,and beta blocker, carvedilol have been formulated
as SNEDDS [36]. SNEDDS are used for enhancing the solubility of anti-inflammatory drugs
such as indomethacin [38]. Fibrinolytic drugs such as simvastatin, atorvastatin, valsartan,
gemfibrozil were also formulated as SNEDDS for improved bioavailability. Super-SNEDDS
of simvastatin show increased bioavailability compared to the conventional SNEDDS due to
the increased drug loading [39]. Solid SNEDDS of valsartan enhanced the bioavailabilty
potential due to the presence of porous carriers and also showed stability for about six months
which is an important factor [40]. Hormones such as ondasteron hydrochloride and insulin
were also delivered orally by using SNEDDS. Solid SNEDDS of ondasteron showed increased
bioavailbility than the pure drug [41]. Insulin was formulated into SNEDDS by first forming
insulin-phospholipid complex (IPC) and this was used as oil phase in the formulation. This
showed good hypoglycemic effect in diabetic Wistar rats for oral administration. Hence IPC
can be used for the oral delivery of insulin [42].
Anti-cancer drugs were also formulated as SNEDDS. They include raloxifene hydrochloride,
cyclosporine A, paclitaxel, flutamide. In raloxifene, the uptake of the drug by endocrine organs
was assessed by administering the SNEDDS in alkalinized and non-alkalinized form to Wistar
rats. Non-alkalinized form showed good uptake by the endocrine organs than the alkalinized
form [43]. SNEDDS pellets of cyclosporine A were formulated by fluid bed coating technique
and this improved the in vivo performance of the drug [44]. The drug release profile of
paclitaxel was improved by SNEDDS [45] and the dissolution rate was also faster compared
to that of the pure drug in flutamide [37, 46].
SNEDDS are given in the form of soft or hard gelatin capsules. They reach the gastro intestinal
tract and the GI motility of the stomach provides the agitation for self-emulsification. Because
of this self-emulsification the drug is given as small droplets with size less than 5μm for
improved solubility. After administering orally, lingual and pancreatic lipases act on the oily
phase of the SNEDDS that result in the formation of emulsified mono-glycerides, di-glycerides
and fatty acids. This in the presence of bile acids leads to the formation of intestinal mixed
micelles. When these mixed micelles pass through the enterocytes, it leads to the formation of
chylomicrons. These drain the drug into the lymphatic vessels and not in the blood vessels
thus bypassing the first pass effect. Thus the oral bioavailability gets increased [37].
2.1.2.1. Advantages of SNEDDS
Advantages of SNEDDS include [36]:
• Protection of sensitive drug substances.
• Selective targeting of drug(s) toward specific absorption window in GIT.
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• Enhanced oral bioavailability enabling reduction in dose.
• High drug payloads.
• It can be easily stored since it belongs to a thermodynamics stable system.
• Fine oil droplets would pass rapidly and promote wide distribution of the drug throughout
the GIT, thereby minimizing the irritation frequently encountered during extended contact
between bulk drug substance and the gut wall.
• As compared with oily solutions, they provide a large interfacial area for partitioning of the
drug between oil and water [36].
2.1.2.2. Disadvantages of SNEDDS
Disadvantages of SNEDDS include [36]:
• Lack of good predicative in vitro models for assessment of the formulations because
traditional dissolution methods do not work, because these formulations potentially are
dependent on digestion prior to release of the drug. To mimic this, an in vitro model
simulating the digestive processes of the duodenum has been developed.
• Need of different prototype lipid based formulations to be developed and tested in vivo in
a suitable animal model
2.1.2.3. Factors affecting SNEDDS
There are many factors that affect SNEDDS viz:
• Drugs which are administered at very high dose are not suitable for SNEDDS, unless they
exhibit extremely good solubility in at least one of the components of SNEDDS, preferably
lipophillic phase. The drugs exhibit limited solubility in water and lipids are most difficult
to deliver by SNEDDS.
• The ability of SNEDDS to maintain the drug in solubilized form is greatly influenced by the
solubility of the drug in oily phase. If the surfactant or co-surfactant is contributing to a
greater extent for drug solubilization, then there could be a risk of precipitation, as dilution
of SNEDDS will lead to lowering of solvent capacity of surfactant or co-surfactant [36].
2.1.3. Solid self-nanoemulsifying drug delivery systems (SSNEDDSs)
Solid SNEDDS was developed in order to eliminate the disadvantages associated with liquid
SNEDDS handling, manufacturing and stability. Solid SNEDDS in the form of dry, solid
powders would help in overcoming the limitations associated with liquid SNEDDS. Solid
dosage forms are most stable and are convenient for handling; therefore, attempts are made
to convert the liquid systems into solid SNEDDS. Various techniques, such as spray drying,
freeze drying and adsorption on carriers, can be employed to convert liquid SNEDDS into
solid SNEDDS compressed into tablets. The selection of a particular process for prepara‐
tion of solid SNEDDS would depend on the content of oily excipient of the formulation,
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properties  of  active  pharmaceutical  ingredients,  such  as  solubility,  heat  stability  and
compatibility with other ingredients [47].
The simplest technique to convert liquid SNEDDS to solid SNEDDS is by adsorption onto the
surface of carriers or by granulation using liquid SNEDDS as a binder. This technique is
uncomplicated, cost effective, easily optimized and industrially scalable. It can be used for
heat-and moisture-sensitive molecules, thus providing an advantage over other techniques,
such as spray drying and freeze drying. Various excipients utilized for the preparation of solid
oral dosage forms can be employed for adsorption. The excipients should possess large surface
areas to adsorb sticky and sometimes viscous oily SNEDDS formulation [47].
The ability of different excipients, such as dibasic calcium phosphate, lactose, microcrystalline
cellulose, colloidal silicon dioxide and Neusilin, to adsorb cefpodoxime proxetil SNEDDS have
been studied [47]. Solidification techniques for converting liquid/semisolid SEDDS/SNEDDS
to solids include:
• Capsule filling with liquid and semisolid self-emulsifying formulations: Capsule filling
is the simplest and the most common technology for the encapsulation of liquid or semi
solid SE formulations for the oral route. The advantages of capsule filling are simplicity of
manufacturing, suitability for low-dose highly potent drugs and high drug loading up to
50% (w/w) potential [48].
• Spray drying: This technique involves the preparation of a formulation by mixing lipids,
surfactants, drug, solid carriers, and solubilization of the mixture before spray drying. The
solubilized liquid formulation is then atomized into a spray of droplets. The droplets are
introduced into a drying chamber, where the volatile phase (e.g. the water contained in an
emulsion) evaporates, forming dry particles under controlled temperature and airflow
conditions. Such particles can be further prepared into tablets or capsules [48].
• Spray cooling: Spray cooling also referred to as spray congealing is a process whereby the
molten formula is sprayed into a cooling chamber. Upon contact with the cooling air, the
molten droplets congeal and re-crystallize into spherical solid particles that fall to the bottom
of the chamber and subsequently collected as fine powder. The fine powder may then be
used for development of solid dosage forms, tablets or direct filling into hard shell capsules.
Many types of equipment are available to atomize the liquid mixture and to generate
droplets: rotary pressure, two-fluid or ultrasonic atomizers [49, 50].
• Adsorption to solid carriers: SEDDS can be adsorbed at high levels (up to 70% (w/w)) onto
suitable carriers. Solid carriers can be microporous inorganic substances, high surface area
colloidal inorganic adsorbent substances, cross-linked polymers or nanoparticle adsorbents
(i.g., silica, silicates, magnesium trisilicate, magnesium hydroxide, talcum, crospovidone,
cross-linked sodium carboxymethyl cellulose and crosslinked polymethyl methacrylate).
The adsorption technique has been successfully applied to gentamicin and erythropoietin
with caprylocaproyl polyoxylglycerides (Labrasol) formulations that maintained their
bioavailability enhancing effect after adsorption on carriers [51-53].
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• Melt granulation: Melt granulation or pelletization is a one step-process allowing the
transformation of a powder mix (containing the drug) into granules or spheronized pellets.
The technique needs high shear mixing in presence of a meltable binder. This is referred to
as “pump-on” technique. Alternatively, the binder may be blended with the powder mix in
its solid or semi-solid state and allowed to melt (partially or completely) by the heat
generated from the friction of particles during high shear mixing referred to as “melt-in”
process. The melted binder forms liquid bridges with the powder particles that shape into
small agglomerates (granules) which can, by further mixing under controlled conditions
transform to spheronized pellets [48].
• Melt  extrusion/Extrusion spheronization:  It  is  a  solvent-free process that  allows high
drug loading (60%) as well as content uniformity. Applying extrusion-spheronization, SE
pellets  of  diazepam  and  progesterone  and  bi-layered  cohesive  SE  pellets  have  been
prepared [54, 55].
3. Advantages, disadvantages and major challenges of nanoemulsions as
drug delivery systems
The advantages of nanoemulsions drug delivery systems include [56-58]:
• The small size of the droplets allows them to deposit uniformly on substrates. Wetting,
spreading and penetration may be also enhanced as a result of the low surface tension of
the whole system and the low interfacial tension of the o/w droplets.
• The very small droplet size causes a large reduction in the gravity force and the Brownian
motion may be sufficient for overcoming gravity. This means that no creaming or sedimen‐
tation occurs on storage.
• The small droplet size also prevents any flocculation of the droplets. Weak flocculation is
prevented and this enables the system to remain dispersed with no separation. Nanoemul‐
sions are thermodynamically stable system and the stability allows self emulsification of the
system
• The small droplets also prevent their coalescence, since these droplets are elastic, surface
fluctuations are prevented.
• Nanoemulsions are suitable for efficient delivery of active ingredients through the skin. The
large surface area of the emulsion system allows rapid penetration of actives. It is non-toxic
and non-irritant so can be easily applied to skin and mucous membranes.
• The transparent nature of the system, their fluidity (at reasonable oil concentrations) as well
as the absence of any thickeners may give them a pleasant aesthetic character and skin feel.
• Unlike microemulsions (which require a high surfactant concentration, usually in the region
of 20 % and higher), nanoemulsions can be prepared using reasonable surfactant concen‐
tration. For a 20 % o/w nanoemulsion, a surfactant concentration in the region of 5 – 10 %
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may be sufficient. Nanoemulsions are usually formulated with surfactants, which are
approved for human consumption (GRAS), they can be taken by enteric route.
• Nanoemulsions can be applied for delivery of fragrance, which may be incorporated in
many personal care products. This could also be applied in perfumes, which are desirable
to be formulated alcohol free.
• Nanoemulsions may be applied as a substitute for liposomes and vesicles (which are much
less stable) and it is possible in some cases to build lamellar liquid crystalline phases around
the nanoemulsion droplets.
• Nanoemulsions can be formulated in numerous dosage foam such as creams, liquids, sprays
and foams.
• They do not damage healthy human and animal cells, so nanoemulsions are suitable for
human and veterinary therapeutic purposes [56].
• Increase the rate of absorption, increases bioavailability and eliminates variability in
absorption
• Helps solubilize lipophilic drug and masks unpleasant taste of some drugs
• Various routes like topical, oral and intravenous can be used to deliver the product.
• Better uptake of oil-soluble supplements in cell cultures. Improve growth and vitality of
cultured cells. It allows toxicity studies of oil-soluble drugs in cell cultures.
• Nanoemulsions could enhance the stability of chemically unstable compounds by protect‐
ing them from oxidative degradation and degradation by light.
• Possibilities of controlled drug release and drug targeting, and the incorporation of a great
variety of therapeutic actives.
3.1. Major challenges
Although nanoemulsions provide great advantages as a delivery system, however they suffer
for some major challenges and limitations which include [56-58]:
• The formulation of nanoemulsions is an expensive process due to size reduction of droplets
is very difficult as it required a special kind of instruments and process methods. For
example, homogenizer (instrument required for the nanoemulsions formulation) arrange‐
ment is an expensive process. More ever micro-fluidization and ultrasonication (manufac‐
turing process) require large amount of financial support.
• One problem associated with nanoemulsion is their stability. Although it is generally
accepted that these systems could remain stable even by years, however, due to the small
droplet size, it has been reported that the Oswald ripening could damage nanoemulsions,
causing their application to be limited. Therefore, in most cases, nanoemulsions are required
to be prepared shortly before their use.
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• Use of a large concentration of surfactant and cosurfactant necessary for stabilizing the nano
droplets.
• Limited solubility capacity for high melting substances.
• Nanoemulsion stability is influenced by environmental parameters such as temperature and
pH.
• Lack of understanding of the mechanism of production of submicron droplets and the role
of surfactants and cosurfactants.
• Lack of demonstration of the benefits that can be obtained from using nanoemulsions when
compared with the classical macroemulsion systems.
• Lack of understanding of the interfacial chemistry that is involved in production of
nanoemulsions.
4. Formulation of nanoemulsions
4.1. Materials used in preparation of nanoemulsions
Nanoemulsions are prepared using oils, surfactants and co-surfactants and aqueous phase
[59]. Oils used in nanoemulsions preparation include Captex 355, Captex 8000, Witepsol,
Myritol 318, Isopropyl myristate, Capryol 90, Sefsol-218, triacetin, isopropyl myristate, castor
oil, olive oil, etc. Solubility of the drug in the oil phase is an important criterion for the selection
of oils. This is particularly important in the case of oral formulation development, as the ability
of nanoemulsion to maintain the drug in solubilized form is greatly influenced by the solubility
of the drug in the oil phase. While water-in-oil nanoemulsions are better choice for hydrophilic
drugs lipophilic drugs are preferably solubilized in oil-in-water nanoemulsions. Drug loading
in the formulation is a very critical design factor in the development of nanoemulsions for
poorly soluble drugs, which is dependent on the drug solubility in various formulation
components. An understanding of factors influencing drug loading capacity while maintain‐
ing the capability of the system to undergo monophasic dilution with water and minimizing
the tendency for drug precipitation or crystallization in diluted systems is essential to the
design of stable and appropriately low-volume nanoemulsion systems for drug delivery
applications [60,61]. Edible oils are not frequently useful due to their poor ability to dissolve
large amounts of lipophilic drugs. Moreover, formulation of nanoemulsion with oil of low
drug solubility would require incorporation of more oil to incorporate the target drug dose,
which in turn would require higher surfactant concentration to achieve oil solubilization,
which might increase the toxicity of the system. Novel semi-synthetic medium chain deriva‐
tives (as amphiphilic compounds) having surfactant properties are progressively and effec‐
tively replacing the regular medium chain triglyceride oils [62,63].
Surfactants used for stabilizing nanoemulsions may be non ionic, zwitterionic, cationic and
anionic. The surfactants may include Capryol 90, Gelucire 44/14, 50/13, Cremophor RH 40,
Imwitor 191, 742, 780 k, 928, 988, Labrafil CS, M, 2125 CS, Lauroglycol 90, PEG MW > 4000,
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Plurol Oleique CC 497, Poloxamer 124 and 188, Softigen 701, 767, Labrasol, Cremophor EL,
Tween 20, Tween 60, and Tween 80, etc. Components of nanoemulsion-based systems are
associated with toxicity concerns. Large amounts of surfactants may cause gastrointestinal and
skin irritation when administered orally and topically, respectively. Therefore, the proper
selection of surfactants is essential. Rational use of the minimum concentration of the surfactant
in the formulation is advocated. Nonionic surfactants are relatively less toxic than their ionic
counterparts and typically have lower critical micelle concentration (CMCs). Also, o/w
nanoemulsion dosage forms for oral or parenteral use based on nonionic surfactants are likely
to offer in vivo stability [64]. Therefore, proper selection of surfactants is a crucial factor.
Another important criterion is the selection of surfactant with proper hydrophile-lipophile-
balance (HLB) value. Hydrophilic surfactants and co-surfactants are considered to prefer the
interface and to lower the necessary energy to form the nanoemulsions, thereby improving
the stability. For instance, the required HLB value to form o/w nanoemulsion is greater than
10 [65]. The right blend of low and high HLB surfactants leads to the formation of a stable
nanoemulsion upon dilution with water. The type and nature of the surfactant is also an
important factor for consideration; nonionic surfactants are usually selected since they are
known to be less affected by pH and changes in ionic strength, are generally regarded as safe,
and are biocompatible; ionic surfactants are less commonly used due to toxicological concerns.
Solubilization of oil with the surfactant is also an important factor. It is not necessary that the
same surfactant that has good solubilizing power for drugs would have equally good affinity
for the oil phase. Surfactant–oil miscibility can thus give an initial indication on the possibility
of nanoemulsion formation with this system.
Cosurfactants are added to obtain nanoemulsion systems at low surfactant concentration [66].
Short-to medium-chain-length alcohols (C3–C8) are commonly added as cosurfactants, which
further reduce the interfacial tension and increase the fluidity of the interface [67,68]. They also
increase the mobility of the hydrocarbon tail and allow greater penetration of the oil into this
region. Alcohols may also increase the miscibility of the aqueous and oily phases due to its
partitioning between these phases. Co-surfactants used in nanoemulsions include Transcutol
P, glycerin, ethyleneglycol, ethanol, propanol, ethanol, isopropyl alcohol, n-butanol, PEG 400,
Carbitol, and propylene glycol. Nanoemulsion area is often used as the assessment criterion
for the evaluation of cosurfactants. The larger the size of the nanoemulsion field, the greater
the nanoemulsification efficiency of the system.
Moreover, the most important criterion for selection of all the nanoemulsion components is
that all the excipients should be pharmaceutically acceptable for oral administration or topical
application, etc., depending upon the requirement and falling under GRAS category.
4.2. Methods of preparation of nanoemulsions
As nanoemulsions are non-equilibrated systems [69-71], and so their preparation involves the
input of a large amount of either energy or surfactants and in some cases a combination of
both. As a result, high energy or low energy methods can be used in their formulation [70].
Although high energy emulsification method is traditionally used for the preparation of
nanoemulsion formulation but low emulsion emulsification method now create an attraction
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due to their wide application and advantages as a formulation and stability aspects. Generally,
energy is usually required in emulsion formulation because the process may be non-sponta‐
neous. The production of nanoemulsions costs more energy than that required to produce
macroemulsions. Presence of surfactants help lower the surface tensions between oil and
water. Small molecules such as non-ionic surfactants lower surface tension more than poly‐
meric surfactants such as poly (vinyl alcohol). Another important role of the surfactant is its
effect on the interfacial dilatational modulus [72]. During emulsification an increase in the
interfacial area takes place and this causes a reduction in surface excess. The equilibrium is
restored by adsorption of surfactant from the bulk, but this takes time (shorter times occur at
higher surfactant activity). Because of the lack or slowness of equilibrium with polymeric
surfactants, dilatational modulus will not be the same for expansion and compression of the
interface [72]. In practice, surfactant mixtures are used and these have pronounced effects on
surface tension and dilatational modulus. Some specific surfactant mixtures give lower surface
tension values than either of the two individual components. Polymer-surfactant mixtures may
show some synergistic surface activity. An important role of the emulsifier is to prevent shear-
induced coalescence during emulsification. The requirement is that the continuous phase has
a significant excess of surfactant. This excess enables new surface area of the nano-scale
droplets to be rapidly coated during emulsification, thereby inhibiting shear-induced coales‐
cence. This excess is generally in the form of surfactant micelles in the continuous phase. These
micelles dissociate into monomers that rapidly adsorb onto the surfaces of newly created
droplets [71].
4.2.1. Low energy methods
As the name suggests, low-energy emulsification methods require low energy for the fabrica‐
tion of nanoemulsions. These methods are mainly dependent on modulation of interfacial
phenomenon/phase transitions and intrinsic physicochemical properties of the surfactants, co-
emulsifiers/co-surfactants and oil to yield nano-sized emulsion droplets. The lower energy
method, also called the condensation method, is based on the phase transitions taking place
during the emulsification process [73,74]. These phase transitions result from changes in the
spontaneous curvature of the surfactant and can be achieved (i) at constant composition by
changing the spontaneous curvature of non-ionic surfactants with temperature, the well-
known Phase Inversion Temperature, PIT, widely used in industry [75,76] or (ii) at constant
temperature by varying the composition of the system by the Emulsion Inversion Point (EIP)
method [77-79]. In other words, low-energy emulsification method was developed according
to the phase behavior and properties of the constituents, to promote the formation of ultra-
small droplets [80,81]. These low-energy techniques include self-emulsification, phase
transition and phase inversion temperature methods [82]. The low energy method is interest‐
ing because it utilizes the stored energy of the system to form small droplets. This emulsifica‐
tion can be brought about by changing the parameters which would affect the hydrophilic
lipophilic balance (HLB) of the system like temperature, composition, etc. [83,84]. The
limitations include complexity, precise approach required and use of synthetic surfactants. In
a nutshell, the most commonly used low-energy emulsification methods include:
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4.2.1.1. Phase Inversion Temperature (PIT) method
This method employs temperature-dependent solubility of non-ionic surfactants, such as
polyethoxylated surfactants, to modify their affinities for water and oil as a function of the
temperature. It has been observed that polyethoxylated surfactants tend to become lipophilic
on heating owing to dehydration of polyoxyethylene groups. This phenomenon forms a basis
of nanoemulsion fabrication using the PIT method. In the PIT method, oil, water and nonionic
surfactants are mixed together at room temperature. This mixture typically comprises o/w
microemulsions coexisting with excess oil, and the surfactant monolayer exhibits positive
curvature. When this macroemulsion is heated gradually, the polyethoxylated surfactant
becomes lipophilic and at higher temperatures, the surfactant gets completely solubilized in
the oily phase and the initial o/w emulsion undergoes phase inversion to w/o emulsion. The
surfactant monolayer has negative curvature at this stage [75]. At an intermediate temperature
(also termed HLB temperature), the non-ionic surfactant has similar affinity for aqueous and
oily phase, and this ternary system has extremely low interfacial tension (in the order of 10−2–
10–5 mNm−1) and spontaneous curvature typically reaches zero [83,84]. The ternary system at
this stage typically consists of a D-phase bicontinuous microemulsion or a mixture of a D-
phase bicontinuous microemulsion and lamellar liquid crystalline phases. It has been observed
that nanoemulsions with very small droplet size and polydispersity index can be generated
by rapid cooling of the single-phase or multiphase bicontinuous microemulsions maintained
at either PIT or a temperature above PIT (transitional-phase inversion) [76]. Nanoemulsions
can also be generated by rapidly diluting the single bicontinuous microemulsions with the
aqueous or oil phase (catastrophic phase inversion) to obtain either o/w nanoemulsion or
w/o nanoemulsion. It has been observed that the characteristics of the nanoemulsion are
mainly dependent on the structure of the surfactant at HLB temperature (bicontinuous or
lamellar) and also on the surfactant/oil ratio. Initially, PIT method was believed to be useful
for fabricating o/w nanoemulsions. However, in recent years, the application of the PIT method
has been established for fabricating w/o emulsions and nanoemulsions. It is important to note
that the use of lipophilic polyethoxylated surfactants and appropriate modifications in the
typical PIT protocol are required for obtaining w/o nanoemulsions [82].
4.2.1.2. Solvent displacement method
The solvent displacement method for spontaneous fabrication of nanoemulsion has been
adopted from the nano-precipitation method used for polymeric nanoparticles. In this method,
oily phase is dissolved in water-miscible organic solvents, such as acetone, ethanol and ethyl
methyl ketone. The organic phase is poured into an aqueous phase containing surfactant to
yield spontaneous nanoemulsion by rapid diffusion of organic solvent. The organic solvent is
removed from the nanoemulsion by a suitable means, such as vacuum evaporation [78-81].
4.2.1.3. Phase Inversion Composition Method (Self-nanoemulsification Method)
This method generates nanoemulsions at room temperature without use of any organic solvent
and heat. Forgirani et al. observed that kinetically stable nanoemulsions with small droplet
size (~50 nm) can be generated by the stepwise addition of water into solution of surfactant in
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oil, with gentle stirring and at constant temperature [77]. Although the components used in
the aforementioned investigation were not of pharmaceutical grade, the investigation opened
doors to design pharmaceutically acceptable nanoemulsions using a similar approach. The
spontaneous nano-emulsification has been related to the phase transitions during the emulsi‐
fication process and involves lamellar liquid crystalline phases or D-type bicontinuous
microemulsion during the process [77].
4.2.2. High energy methods
High-energy emulsification methods make use of devices that use very high mechanical
energy to create nanoemulsions with high kinetic energy. The high-energy method utilizes
mechanical devices to create intensely disruptive forces which break up the oil and water
phases to form nano-sized droplets. This can be achieved with ultrasonicators, microfluidiser
and high pressure homogenisers [71,85,86]. Particle size here will depend on the type of
instruments employed and their operating conditions like time and temperature along with
sample properties and composition [87]. These methods include high-pressure homogeniza‐
tion and ultrasonic emulsification. High-pressure homogenization is the most common
method used for the fabrication of nanoemulsions. During high-pressure homogenization, the
coarse macroemulsion is passed through a small orifice at an operating pressure in the range
of 500 to 5000 psi. During this process, several forces, such as hydraulic shear, intense turbu‐
lence and cavitation, act together to yield nanoemulsions with extremely small droplet size.
The resultant product can be re-subjected to high-pressure homogenization until nanoemul‐
sion with desired droplet size and polydispersity index is obtained [71]. Micro-fluidization
employs a high-pressure positive displacement pump operating at very high pressures, up to
20,000 psi. This pump forces macroemulsion droplets through the interaction chamber
consisting of a series of micro-channels. The macroemulsion flowing through the microchan‐
nels collides with high velocity on to an impingement area resulting in very fine nanoemul‐
sions. The nanoemulsions with desired size range and dispersity can be obtained by varying
the operating pressure and the number of passes through interaction chambers like high-
pressure homogenization. Ultrasonic emulsification uses a probe that emits ultrasonic waves
to disintegrate the macroemulsion by means of cavitation forces. By varying the ultrasonic
energy input and time, the nanoemulsions with desired properties can be obtained [85-87].
High-energy emulsification methods can be employed to fabricate both o/w and w/o nanoe‐
mulsions. High-pressure homogenization and microfluidization can be used for fabrication of
nanoemulsions at laboratory and industrial scale, whereas ultrasonic emulsification is mainly
used at laboratory scale. In addition, high-energy methods require sophisticated instruments
and extensive energy input, which considerably increases the cost of nanoemulsions fabrica‐
tion. This is particularly significant in the pharmaceutical sciences [85-87]. High energy
methods allow for a greater control of particle size and a large choice of composition, which
in turn controls the stability, rheology and colour of the emulsion. Although high-energy
emulsification methods yield nanoemulsions with desired properties and have industrial
scalability, they may not be suitable for thermolabile drugs such as retinoids and macromo‐
lecules, including proteins, enzymes and nucleic acids. Moreover, high energy methods alone
normally do not yield oil droplets (<100 nm).
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4.3. Formulation factors that affect the stability of nanoemulsions
Although nanoemulsions enhance the physical as well as chemical stability of drugs, stability
of drug product is one of the problems associated with the development of nanoemulsions
[88-91]. Stability studies are performed on nanoemulsions by storing them at refrigerator and
room temperatures over a number of months. The viscosity, refractive index and droplet size
are determined during this period of storage. Insignificant changes in these parameters
indicate formulation stability. Accelerated stability studies can also be performed on the
nanoemulsions. In this instance, nanoemulsion formulation are kept at accelerated tempera‐
tures and samples withdrawn at regular intervals and analyzed for drug content by stability
indicating assay methods. The amount of drug degraded and remaining in nanoemulsion
formulation is determined at each time interval [92]. Stability of nanoemulsion formulation
may be enhanced by controlling factors such as type and concentration of surfactant and co-
surfactant, type of oil phase, methods used, process variables and addition of additives [88-93].
Overall nanoemulsion formulation may be considered as effective, safe and patient compliance
formulation for the delivery of pharmaceuticals.
Factors to be considered during preparation of nanoemulsion include the following among
others [93]:
a. The prime requirement in nanoemulsion production is that an ultra low interfacial tension
should be attained at the oil water interface, so surfactants must be carefully chosen.
b. Concentration of surfactant must be high enough to provide the number of surfactant
molecules needed to stabilize the nano droplets.
c. The interface must be flexible to promote the formation of nanoemulsion.
5. Characterization of nanoemulsions
Characterization of nanoemulsions involves the physical and chemical tests related to oral
liquid dosage forms which includes compatibility of the nanoemulsion components, isotro‐
picity of the formulation, assay, uniformity of content, appearance, pH, viscosity, density,
conductivity, surface tension, size and zeta potential of the dispersed phase etc. with respect
to the effect of the composition on physical parameters [94-104]. Differential scanning calo‐
rimetry (DSC) provides information on the interactions of different components and polari‐
zation microscopy using crossed polarizers is employed to confirm isotropicity of the
formulation [99]. The process of self-nanoemulsification can be evaluated by visual assess‐
ment. Its efficiency would be estimated by determining the rate of emulsification and droplet
size distribution. Turbidity measurements are carried out to determine the rapid equilibrium
reached by the dispersion and reproducibility of this process. The droplet size of the emulsion
is a crucial factor in self-nanoemulsification performance because it determines the rate and
extent of drug release as well as absorption. Photon correlation spectroscopy (PCS) and light
scattering techniques like static light scattering (SLS), dynamic light scattering (DLS) are a
useful method for determination of nanoemulsion droplet size [100]. Viscosity, conductivity
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and dielectric methods provide useful information at the macroscopic level. Viscosity meas‐
urements for example can indicate the presence of rod-like or worm-like reverse micelles and
conductivity measurements provide the means of determining whether a nanoemulsion is oil-
continuous or water-continuous, as well as providing a means of monitoring phase inversion
phenomena [99]. Dielectric measurements are a powerful means of probing both the structural
and dynamic features of nanoemulsion system. Structural features of nanoemulsions have
been studied using self-diffusion nuclear magnetic resonance (SD NMR) and small angle x-
ray scattering (SAXS). Freeze fracture electron microscopy has also been used to study
nanoemulsion structure, however extremely rapid cooling of the sample is required in order
to maintain the structure and minimize the possibility of artifacts [101-103]. Nanoemulsion
droplet polarity is also a very important factor in characterizing emulsification efficiency. The
HLB, chain length and degree of unsaturation of fatty acids, molecular weight of the hydro‐
philic portion and concentration of the emulsifier have an impact on the polarity of the oil
droplets. Polarity represents the affinity of the drug compound for oil and/ or water and the
type of forces formed. Rapid release of the drug into the aqueous phase is promoted by the
polarity. The charge of the oil droplets of nanoemulsions is another property that should be
assessed. Usually it is negative due to the presence of free fatty acids; however, incorporation
of a cationic lipid, such as oleylamine at a concentration range of 1-3%, will yield cationic
nanoemulsions [104,105].
The following sub-headings could be used to discuss briefly the parameters commonly
employed in the assessment of nanoemulsions:
a. Morphology: The morphology of nanoemulsions can be determined by transmission
electron microscopy (TEM) and scanning electron microscopy (SEM). SEM gives a three-
dimensional image of the globules [105]. The samples are examined at suitable accelerat‐
ing voltage, usually 20 kV, at different magnifications. A good analysis of surface
morphology of disperse phase in the formulation is obtained through SEM. Image analysis
software may be employed to obtain an automatic analysis result of the shape and surface
morphology [106]. In TEM, higher resolution images of the disperse phase are obtained.
The sample is negatively stained with 1% aqueous solution of phosphotungstic acid or by
dropping 2 % uranyl acetate solution onto a 200 μm mesh size Pioloform™-coated copper
grid or a microscopic carbon-coated grid using a micropipette and the sample examined
under a transmission electron microscope at appropriate voltage. Qualitative measure‐
ments of sizes and size distribution of TEM micrographs can be performed using a digital
image processing programme [107]. More sophisticated techniques, such as x-ray or
neutron scattering, atomic force microscopy, or cryo-electron microscopy are typically
required to explore the structure and behaviour of nanoemulsions [71].
b. Droplet size, polydispersity and zeta potential: Dynamic light scattering (DLS) otherwise
called photon correlation spectroscopy (PCS) is used to analyze the fluctuations in the
intensity of scattering by droplets/particles due to Brownian motion [108]. Nanoemulsion
droplet size, polydispersity and zeta potential can be assessed by PCS using a particle size
analyzer. This instrument also measures polydispersity index, which is a measure of the
broadness of the size distribution derived from the cumulative analysis of dynamic light
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scattering. The polydispersity index indicates the quality or homogeneity of the dispersion
[109]. PCS gives z-average particle diameter. Laser diffraction is another technique for
measuring particle size. The fundamental particle size distribution derived by this
technique is volume based and is expressed in terms of the volume of equivalent spheres
(DN%) and weighted mean of the volume distribution (mass mean diameter). Since the
laser diffraction system is used for this analysis, a rough equivalent of particle polydis‐
persity could be given by two factors/values namely, uniformity (how symmetrical the
distribution is around the median point) and span (the width of the distribution). The
span value is defined by the expression:
( )Span 90% 10% / 50%D D D= - (2)
Where DN% (N=10%, 50%, 90%), means that the volume percentage of particles with diameters
up to DN% equals to N%. The smaller the span value the narrower the particle size distribution.
c. Viscosity: This is carried out using a viscometer. The viscosity of nanoemulsions is a
function of the surfactant, water and oil components and their concentrations. Increasing
the water content lowers the viscosity, while decreasing the amount of surfactant and
cosurfactant increases interfacial tension between water and oil resulting in increased
viscosity. Viscosity is very important for stability and efficient drug release. Nanoemul‐
sion carrier formulations are basically oil-in-water and so in addition to being less greasy
than water-in-oil formulations, often possess lower apparent viscosities. They are
therefore expected to exhibit faster release of active ingredients and wash out easily after
application on the skin surface. Various equipment and methods are available for
assessment of rheological properties of nanoemulsion carriers. Monitoring of viscosity
change is a method of assessing stability of liquid and semi-solid preparations including
nanoemulsion formulations [99].
d. In vitro skin permeation: Franz diffusion cell is used to obtain the drug release profile of
the nanoemulsion formulation in the case of formulations for transdermal application.
The extent or depth of skin penetration by the released content can be visualized by
confocal scanning laser microscopy. In vitro drug release can be determined by dispersing
an amount of the preparation in the donor compartment of a Franz cell having a membrane
as barrier and monitoring the appearance of the encapsulated drug in the receptor
compartment, usually containing phosphate buffer saline (PBS, pH 7.4) and stirring on a
magnetic stirrer at 100 rpm at 37 ± 1 °C. Samples (1 ml) of the dispersion are withdrawn
from the receptor medium and replaced with an equivalent amount of the medium at
definite intervals. The withdrawn sample is then filtered using a 0.22-50 μm filter (e.g.,
Millipore, USA) and the drug released then analyzed using HPLC or UV-Vis spectroscopy
at wavelength of peak absorption of the drug [110]. An alternative and popular method
of ex-vivo release study is performed using diffusion cell. The skin is cut from the ear or
abdomen and underlying cartilage and fats carefully removed. Appropriate size of skin
is cut and placed on the diffusion cell which had earlier been filled with receptor solution.
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Samples of the vesicular preparation are then applied on the dorsal surface of the skin and
the instrument started. At intervals, up to 24 h, samples are withdrawn from the receptor
medium and replaced with equal amounts of the medium and the withdrawn samples
analyzed for the drug permeated using HPLC or UV spectroscopy [111,112]. Semi-
permeable membrane such as regenerated cellulose could be used in place of skin for in
vitro release studies [113,114]. The flux J, of the drug across the skin or membrane is
calculated from the formula:
J=Ddc/dx (3)
Where D is the diffusion coefficient and is a function of the size, shape and flexibility of the
diffusing molecule as well as the membrane resistance, c is the concentration of the diffusing
species, x is the spatial coordinate [114].
e. In vivo bioavailability/pharmacodynamic studies: In vivo release study otherwise
referred to as dermatopharmacokinetics, is carried out by applying or administering the
preparation to whole live animal. Blood samples are then withdrawn at intervals,
centrifuged and the plasma (deproteinated) analyzed for the drug content using HPLC.
Results obtained from in vitro and in vivo studies are extrapolated to reflect bioavailability
of the drug formulation. Moreover, the pharmacodynamic properties of nanoemulsion
formulations are also assessed depending on the pharmacological properties of the
incorporated drug [81-93,95,101].
6. Applications of nanoemulsions in drug delivery
Nanoemulsions could be and have been applied in various aspects of drug delivery including:
cosmetics and transdermal delivery of drug, cancer therapy, vaccine delivery, prophylactic in
bio-terrorism attack, non-toxic disinfectant cleaner, cell culture technology, formulations for
improved oral delivery of poorly soluble drug, ocular and otic drug delivery, intranasal drug
delivery, parenteral drug delivery and pulmonary delivery of drugs.
6.1. Applications in cosmetics
Recently importance of nanoemulsions have become increasing as good vehicles for the
controlled delivery of cosmetics and for the optimized dispersion of active ingredients in
particular skin layers. Due to their lipophilic interior, nanoemulsions are more suitable for the
transport of lipophilic drug than liposomes Similar to liposomes, nanoemulsions supports the
skin penetration of active ingredients and thus increases their concentration in the skin.
Another advantage is the small-sized droplet with its high surface area permit effective
delivery of the active to the skin. More ever, nanoemulsions gain increasing interest due to
their own bioactive effects. This may reduce the trans-epidermal water loss (TEWL), suggest‐
ing that the barrier function of the skin is strengthened. Nanoemulsions are acceptable in
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cosmetics because there is no chance of creaming, sedimentation, flocculation or coalescence,
which is observed within microemulsions. The incorporation of potentially irritating surfac‐
tants can be avoided by using high-energy equipment during manufacturing process. PEG-
free nanoemulsions for cosmetics has also been developed and formulations exhibited good
stability [56-58,115,116].
6.2. Antimicrobial nanoemulsions
Antimicrobial nanoemulsions are o/w droplets that range from 200-600 nm. They are made of
oil and water and are stabilized by surfactants and alcohol. The nanoemulsions has a broad
spectrum of activity against bacteria like E. coli, salmonella, S. aureus; enveloped viruses like
HIV, herpes simplex; fungi like candida, dermatophytes, and spores like anthrax. The
nanoemulsions particles are thermodynamically driven to fuse with lipid-containing organ‐
isms. This fusion is enhanced by the electrostatic attraction between the cationic charge of the
emulsion and the anionic charge on the pathogen. When enough nanoparticles fuse with the
pathogens, they release part of the energy trapped within the emulsion. Both the active
ingredient and the energy released destabilize the pathogen lipid membrane, resulting in cell
lysis and death. In the case of spores, additional germination enhancers are added into the
emulsion. Once starting of germination takes place, the germinating spores become susceptible
to the antimicrobial action of the nanoemulsions. An aspect of the nanoemulsions is their
highly selective toxicity to microbes at concentration range that are non-irritating to skin or
mucous membrane. The safety range of nanoemulsions is because of the low amount of
detergent in each droplet, yet when acting in concert, these droplets have enough energy and
surfactant to destabilize targeted microbes without affecting healthy cells. Nanoemulsions can
get a level of topical antimicrobial activity, which can only be previously achieved by systemic
antibiotics [56-58,115].
6.3. Prophylactic in bio-terrorism attack
Because of their antimicrobial activity, research has begun on use of nanoemulsions as a
prophylactic medicated dosage form, a human protective treatment, to prevent the people
exposed to bio-attack such as Anthrax and Ebola. The broad-spectrum nanoemulsions were
checked on surfaces by the US Army (RestOps) in Dec 1999 for decontamination of Anthrax
spore. It was checked again by RestOps in March 2001 as a chemical decontamination agent.
This technology has been tested on gangrene and clostridium botulism spores, and can even
be used on contaminated wounds to salvage limbs. The nanoemulsions can be formulated into
a cream, foam, liquid and spray to decontaminate a large number of materials, which is
marketed as NANOSTAT™ (Nanobio Corp.) [56-58,115].
6.4. Nanoemulsions in vaccines delivery
This medication delivery system uses nanotechnology to vaccinate against human immuno‐
deficiency virus (HIV). There is recent evidence that HIV can infect the mucosal immune
system. Therefore, developing mucosal immunity through the use of nanoemulsions may
become very important in the future fight against HIV [50]. The oil-based emulsion is admin‐
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istered in the nose, as opposed to traditional vaccine routes. Recent research results indicate
that genital mucosa immunity may be attained with vaccines that are administered into the
nasal mucosa [56-58,115]. Nanoemulsions are being used to transport inactivated organisms
to a mucosal surface to produce an immune response. The first applications as vaccine, an
influenza vaccine and an HIV vaccine, can proceed to clinical trials. The nanoemulsion causes
proteins applied to the mucosal surface to be adjuvant and it help uptake by antigen presenting
cells. This results in the significant systemic and mucosal immune response due to that the
production of specific IgG and IgA antibody as well as cellular immunity. Work in influenza
has shown that animals can be prevented against influenza after a single mucosal exposure to
the virus mixed with thenanoemulsions. Research has also show that animals exposed to
recombinant gp120 in nanoemulsions on their nasal mucosa create significant responses to
HIV, thus giving a basis to use of this material as an HIV vaccine. Additional research has been
ongoing to complete the proof of concept in animal trials for other vaccines including Anthrax
and Hepatitis B. The University of Michigan has licensed this technology to NanoBio [56].
6.5. Nanoemulsions as non-toxic disinfectant cleaner
Nanemulsions have been employed as a disinfectant cleaner. A nontoxic disinfectant cleaner
for use in routine markets that include healthcare, travel, food processing and military
applications has been developed by EnviroSystems. They have been found to kill tuberculosis
and a large spectrum of viruses, bacteria and fungi within 5 to 10 min without any of the
hazards posed by other categories of disinfectants. The product requires no warning labels. It
does not irritate eyes and can be absorbed through the skin, inhaled or swallowed with
harmless effects. The disinfectant formulation is made up of nanospheres of oil droplets less
than 100 μm which are suspended in water to produce a nanoemulsions requiring only small
amounts of the active ingredient, parachlorometaxylenol. The nanospheres have surface
charges that efficiently penetrate the surface charges on microorganisms’ membranes like
breaking through an electric fence. Rather than 'drowning' cells, the formulation allows
parachlorometaxylenol to target and penetrate cell walls. So parachlorometaxylenol is
applicable at concentration ranges I-2 times lower than those of other disinfectants, so there
are no toxic effects on human, animals or the environment [56-58,115].
Other microbial disinfectants need large doses of their respective active ingredients to
surround pathogen cell wall, which causes microbe to disintegrate, ideally 'drowning' them
in the disinfectant solution. The disinfectant is not flammable and so safe to store anywhere
and to use in unstable conditions. It is non oxidizing, non acidic and nonionic. It will not
corrode plastic, metals or acrylic, so it makes the product ideal for use on equipment and
instruments. It is environmentally safe so the economical cost and health risks associated with
hazardous chemical disposal are removed. The preparation is a broad-spectrum disinfectant
cleaner that can be applied to any hard surface, including equipment, walls, fixtures, counters,
and floors. One product can now take the place of many other, decreasing product inventories
and saving valuable storage space. Chemical disposal costs can be removed, and disinfection
and cleaning costs can be reduced. Marketed as EcoTru ™ (EnviroSystems) [56-58,115].
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6.6. Nanoemulsions in cell culture technology
Cell cultures are used for in vitro assays or to produce biological compounds like an antibodies
or recombinant proteins. For optimization of cell growth, the culture medium can be supple‐
mented with a large number of molecules or with blood serum. It has been very difficult to
provide the media with oil-soluble substances that are available to the cells, and only few
amounts of the lipophilic compounds could be absorbed by the cells. Nanoemulsions are a
new method for the delivery of oil-soluble substances to human cell cultures. The system is
based on a nanoemulsions that is stabilized by phospholipids. This nanoemulsions is trans‐
parent and can be passed through 0.1 mm filters for sterilization. Nanoemulsions oil droplets
are very easily taken up by the cells. The encapsulated oil-soluble substances therefore have a
high bioavailability to cells in culture.
The advantages of using nanoemulsions in cell culture technology include:
• Better uptake of oil-soluble supplements in cell cultures.
• Improve growth and vitality of cultured cells.
• Allows toxicity studies of oil-soluble drugs in cell cultures [52 – 55].
6.7. Nanoemulsion formulations for improved oral delivery of poorly soluble drugs
Nanoemulsions formulation was developed to increase oral bioavailability of hydrophobic
drugs. Paclitaxel was selected as a model hydrophobic drug. The o/w nanoemulsions were
made with pine nut oil as the internal oil phase, water as the external phase and egg lecithin
as the primary emulsifier. Stearylamine and deoxycholic acid were used to give positive and
negative charge to the emulsions, respectively. The formulated nanoemulsions had a particle
size range of 100-120 nm and zeta potential ranging from 34 mV to 245 mV. After oral
administration of nanoemulsions, a significantly higher concentration of paclitaxel was
observed in the systemic circulation compare to control aqueous solution. The results of this
study suggest that Nanoemulsions are promising novel formulations which can promote the
oral bioavailability of hydrophobic drugs [56-58,115].
6.8. Nanoemulsions in ocular and otic drug delivery
Ophthalmic drug delivery is one of the most interesting and challenging endeavors facing the
pharmaceutical scientist [117]. It is a common knowledge that the application of eye drops as
conventional ophthalmic delivery systems results in poor bioavailability and therapeutic
response because of lacrimal secretion and nasolacrimal drainage in the eye [118,119]. Most of
the drug is drained away from the precorneal area in few minutes. As a result, frequent
instillation of concentrated solutions is needed to achieve the desired therapeutic effects [120].
But, by the tear drainage, the main part of the administered drug is transported via the
nasolacrimal duct to the gastric intestinal tract where it may be absorbed, sometimes causing
side effects [121]. In order to increase the effectiveness of the drug, a dosage form should be
chosen which increases the contact time of the drug in the eye. This may then increase the
bioavailability, reduce systemic absorption, and reduce the need for frequent administration
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leading to improved patient compliance. Nanoemulsions could be employed to overcome
some of these problems. Dilutable nanoemulsions are potent drug delivery vehicles for
ophthalmic use due to their numerous advantages as sustained effect and high ability of drug
penetration into the deeper layers of the ocular structure and the aqueous humor. Ammar et
al. formulated the antiglaucoma drug dorzolamide hydrochloride as ocular nanoemulsion of
high therapeutic efficacy and prolonged effect [122]. These nanoemulsions showed acceptable
physicochemical properties and exhibited slow drug release. Draize rabbit eye irritation test
and histological examination were carried out for those preparations exhibiting superior
properties and revealed that they were nonirritant. Biological evaluation of dorzolamide
hydrochloride nanoemulsions on normotensive albino rabbits indicated that these products
had higher therapeutic efficacy, faster onset of action, and prolonged effect relative to either
drug solution or the market product. It was concluded from the study that formulation of
dorzolamide hydrochloride in a nanoemulsion form offered a more intensive treatment of
glaucoma, a decrease in the number of applications per day, and a better patient compliance
compared to conventional eye drops.
6.9. Nanoemulsions as a vehicle for transdermal delivery
Drug delivery through the skin to the systemic circulation is convenient for a number of clinical
conditions due to which there has been a considerable interest in this area [123,124]. It offers
the advantage of steady state controlled drug delivery over extended period of time, with self
administration also being possible, which may not be the case with parenteral route. The drug
input can be eliminated at any time by the patient just by removing the transdermal patch.
Their transparent nature and fluidity, confers on nanoemulsions a pleasant skin feel. An extra
advantage is the total absence of gastrointestinal side effects like irritation and bowel ulcers
which are invariably associated with oral delivery. Transdermal drug products have been
developed for a number of diseases and disorders including cardiovascular conditions,
Parkinsons’ and Alzheimer diseases, anxiety, depression, etc. However, the fundamental
disadvantage which limits the use of this mode of administration is the barrier imposed by the
skin for effective penetration of the bioactives. The three routes by which drugs can primarily
penetrate the skin are through the hair follicles, sweat ducts or directly across stratum corneum,
which restricts their absorption to a large extent and limits their bioavailability. For improved
drug pharmacokinetics and targeting, the primary skin barriers need to be overcome. Also the
locally applied drug redistribution through cutaneous blood and lymph vessel system needs
to be controlled. Nano sized emulsions are able to easily penetrate the pores of the skin and
reach the systemic circulation thus getting channelized for effective delivery [69]. Caffeine has
been used for treatment of different types of cancer by oral delivery. Water-in-oil nanoemul‐
sion formulations of caffeine have been developed for transdermal drug delivery. Comparison
of in vitro skin permeation profile between these and aqueous caffeine solutions showed
significant increase in permeability parameters for the nanoemulsion loaded drugs [125]. Use
of nanoemulsions in transdermal drug delivery represents an important area of research in
drug delivery, which enhances the therapeutic efficacy and also the bioavailability of the drugs
without any adverse effects. It is also regarded as a promising technique with many advantages
including high storage stability, low preparation cost, thermodynamic stability, absence of
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organic solvents, and good production feasibility. They have also made the plasma concen‐
tration profiles and bioavailability of drugs reproducible. These systems are being used
currently to provide dermal and surface effects, and for deeper skin penetration [69]. Many
studies have shown that nanoemulsion formulations possess improved trans-dermal and
dermal delivery properties in vitro [66,126-133], as well as in vivo [134-136]. Nanoemulsions
have improved transdermal permeation of many drugs over the conventional topical formu‐
lations such as emulsions and gels [137-141].
Barakat et al prepared nanoemulsions by the spontaneous emulsification method for trans‐
dermal delivery of indomathacin [142]. A significant increase in the permeability parameters
such as steady-state flux, permeability coefficient, and enhancement ratio was observed in
nanoemulsion formulations compared with the conventional indomethacin gel. The anti-
inflammatory effects of nanoemulsion formulations showed a significant increase in percent
inhibition value after 4 hours when compared with conventional indomethacin gel on
carrageenan-induced paw edema in rats. Significant increase in permeability parameters was
observed in nanoemulsion formulations (P< 0.05). The steady-state flux and permeability
coefficient for optimized nanoemulsion formulation (were found to be 22.61±3.45 μg/ cm2/h
and 0.22 x 10−2 ± 0.0003 cm/h, respectively), which were significant compared with conventional
indomethacin gel (P< 0.001). Enhancement ratio was found to be 8.939 in optimized formula‐
tion compared with indomethacin gel. These results suggested that nanoemulsions can be used
as potential vehicles for improved transdermal delivery of indomethacin as an approach to
eliminate the side effect of the oral dose.
Singh et al developed nanoemulsion formulation for transdermal delivery of carvedilol to
enhance the water solubility as well as bioavailability of drug [143]. O/W nanoemulsions were
prepared by the spontaneous emulsification method. Post application plasma carvedilol was
increased 6.41 fold to marketed dosage form. The study suggested that nanoemulsion
significantly enhanced bioavailability of transdermally applied carvedilol and eliminated the
first pass metabolism.
Sajid et al prepared betamethasone valerate nanoemulsions by aqueous phase titration method,
using Sefsol, Tween 20, Transcutol P, and distilled water as the oil phase, surfactant, co
surfactant and aqueous phase, respectively and evaluated them based on the induction of
contact dermatitis in rats using a dispersion of nickel sulfate in solid vaseline at 5%, carra‐
geenan induce inflammation and their irritation study [144]. The optimized nanoemulsion was
converted into hydrogel using Carbopol 934. Drug deposition in skin was found to be 58.46
μg/cm2. In vivo anti-inflammatory activity indicated 84.2% and 45.05% inhibition of inflam‐
mation in case of developed nanoemulsion gel and marketed cream, respectively. The irritation
score was found to be 1.83 which indicates that the optimized nanoemulsion did not cause any
irritation. Results of nickel induced dermatitis demonstrate that the nanoemulsion formulation
gel did not appear to stimulate an inflammatory or immune response using the contact
dermatitis model.
Zhou et al. carried out a study to establish a lecithin nanoemulsion without any synthetic
surfactant as a topical delivery vehicle and to evaluate its topical delivery potential [145].
Experimental results demonstrated that an increasing concentration of soybean lecithin and
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glycerol resulted in a smaller size lecithin nanoemulsion droplet and increasing viscosity,
respectively. Lecithin nanoemulsion, incorporated into o/w cream, improved the skin hydra‐
tion capacity of the cream significantly with about 2.5-fold increase when the concentration of
lecithin nanoemulsion reached 10%. Lecithin nanoemulsion was also demonstrated to improve
the penetrability of Nile red dye into the dermis layer, when an o/w cream, incorporated with
Nile-red-loaded lecithin nanoemulsion, applied on the abdominal skin of rat in vivo. Specifi‐
cally, the arbitrary unit of fluorescence in the dermis layer that had received the cream with a
Nile red-loaded lecithin nanoemulsion was about 9.9-fold higher than the cream with a Nile
red-loaded general emulsion. These observations suggest that lecithin nanoemulsion could be
used as a promising topical delivery vehicle for lipophilic compounds.
Modi et al investigated the potential of a nanoemulsion formulation for topical delivery of
aceclofenac [146]. The in vitro skin permeation profile of optimized formulations was compared
with that of aceclofenac conventional gel and nanoemulsion gel. A significant increase in
permeability parameters such as steady-state flux, permeability coefficient and enhancement
ratio was observed in optimized nanoemulsion formulation consisting of 2 % w/w of aceclo‐
fenac, 10 % w/w of Labrafac, 45% w/w surfactant mixture (Cremophor® EL: Ethanol), and 43
% w/w of distilled water. The anti-inflammatory effects of formulation showed a significant
increased percent inhibition value after 24 hours when compared with aceclofenac conven‐
tional gel and nanoemulsion gel on carrageenan-induced paw edema in rats. These results
suggested that nanoemulsions are potential vehicles for improved transdermal delivery of
aceclofenac.
Batoota et al investigated the potential of nanoemulsion formulations for transdermal delivery
of celecoxib [91]. The in vitro skin permeation profile of optimized formulations was compared
with celecoxib gel and nanoemulsion gel. Significant increase in the steady state flux, perme‐
ability coefficient and enhancement ratio was observed in nanoemulsion formulations (p <
0.05). The highest value of these permeability parameters was obtained in the formulation that
consisted of 2 % (w/w) of celecoxib, 10 % (w/w) of oil phase (Sefsol 218 and Triacetin), 50 %
(w/w) of surfactant mixture (Tween-80 and Transcutol-P) and 40 % (w/w) water. The anti-
inflammatory effects of the formulation showed a significant increase (p < 0.05) in inhibition
after 24 hours compared to celecoxib gel and nanoemulsion gel on carrageenan-induced paw
edema in rats. These results suggested that nanoemulsions are potential vehicles for improved
transdermal delivery of celecoxib.
Harwansh et al evaluated an isotropic and thermodynamically stable nanoemulsion formula‐
tion for transdermal delivery of glycyrrhizin, with minimum surfactant and cosurfactant
concentrations that could improve its solubility, permeation enhancement, and stability [147].
A significant increase in permeability parameters such as steady-state flux and permeability
coefficient was observed in the optimized nanoemulsion formulation, which consisted of 1 %
w/w of mono ammonium glycyrrhizinate, 32.4 % Span 80, 3.7 % Brij 35, 10 % isopropyl alcohol,
46.5 % soyabean oil and 6.4 % distilled water. No obvious skin irritation was observed for the
studied nanoemulsion formulation or the gel. The results indicated that nanoemulsions are
promising vehicles for transdermal delivery of glycyrrhizin through human cadaver skin,
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without the use of additional permeation enhancers, because excipients of nanoemulsions act
as permeation enhancers themselves.
Inayat et al. developed a potential of nanoemulsion formulation for transdermal delivery of
tamoxifene citrate for breast cancer [148]. Transdermal permeation of tamoxifene citrate
through rat skin was determined by Keshary-Chien diffusion cell. A significant increase in
permeability parameter such as steady–state flux was observed in optimized nanoemulsion
formulation, which consist of 5 % w/w of drug, 4.12 % w/w of oil phase, 37.15 % w/w of
surfactant (mix) and 58.73 % w/w of distilled water. It possessed a mean globule size of 68 nm.
Transmission electron microscopy demonstrated spherical particle morphology and DSC and
FTIR study revealed the compatibility among the ingredient. These results proposed that the
prepared system could be promising to improve transdermal efficacy of the tamoxifen citrate.
Shakeel et al investigated the potential of a nanoemulsion formulation for transdermal delivery
of aceclofenac [149]. Transdermal permeation of aceclofenac through rat abdominal skin was
determined by Franz diffusion cell. The in vitro skin permeation profile of optimized formu‐
lations was compared with that of aceclofenac conventional gel and nanoemulsion gel. A
significant increase in permeability parameters such as steady-state flux, permeability
coefficient, and enhancement ratio was observed in optimized nanoemulsion formulation,
which consisted of 2 % w/w of aceclofenac, 10% w/w of Labrafil R, 5 % w/w of Triacetin R,
35.33 % w/w of Tween 80 R, 17.66 % w/w of Transcutol PR, and 32 % w/w of distilled water.
The anti-inflammatory effects of optimized formulation showed a significant increase in
percent inhibition value after 24 hours when compared with aceclofenac conventional gel and
nanoemulsion gel on carrageenan-induced paw edema in rats. These results suggested that
nanoemulsions are potential vehicles for improved transdermal delivery of aceclofenac.
Shakeel et al presented an overview of the efforts that have been made in the last decade by
various researchers in exploring new types of nanoemulsion-based drug delivery system for
dermal and transdermal delivery of many hydrophobic compounds [150]. This area of research
would be very advantageous for formulation scientists in order to develop some nanoemul‐
sion-based formulations for their commercial exploitation and clinical applications. Moreover,
Harwansh et al reviewed efforts made by various researchers in the delivery of phytophar‐
maceuticals using nanoemulsions [151].
6.10. Nanoemulsion in cancer therapy and in targeted drug delivery
Another interesting application, which is experiencing an active development, is the use of
nanoemulsion formulations, for controlled drug delivery and targeting [82]. Because of their
submicron size, they can easily be targeted to the tumor area. Although nanoemulsions are
chiefly seen as vehicles for administering aqueous insoluble drugs, they have more recently
received increasing attention as colloidal carriers for targeted delivery of various anticancer
drugs, photosensitizers, neutron capture therapy agents, or diagnostic agents. The develop‐
ment of magnetic nanoemulsions is an innovative approach for cancer therapy. These can
deliver photosensitizers like Foscan® to deep tissue layers across the skin thereby inducing
hyperthermia for subsequent free radical generation. This methodology can be used for the
treatment of cancer in the form of photodynamic therapy [152].
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6.11. Nanoemulsions and intranasal drug delivery
Intranasal drug delivery system has now been recognized as a reliable route for the adminis‐
tration of drugs next to parenteral and oral routes. Nasal mucosa has emerged as a therapeut‐
ically viable channel for the administration of systemic drugs and also appears to be a
favourable way to overcome the obstacles for the direct entry of drugs to the target site [153].
This route is also painless, non-invasive and well tolerated. The nasal cavity is one of the most
efficient sites because of its reduced enzymatic activity, high availability of immunoactive sites
and its moderately permeable epithelium [154]. There are several problems associated with
targeting drugs to brain, especially the hydrophilic ones and those of high molecular weight.
This is because of the impervious nature of the endothelium, which divides the systemic
circulation and barrier between the blood and brain [155]. The olfactory region of the nasal
mucosa provides a direct connection between the nose and brain, and by the use of nanoe‐
mulsions loaded with drugs, conditions such as Alzheimer’s disease, migraine, depression,
schizophrenia, Parkinson’s diseases, meningitis, etc. can be treated [156,157]. Preparation of
nanoemulsions containing risperidone for its delivery to the brain via nose has been reported
[158]. It is inferred that this emulsion is more effective through the nasal rather than intrave‐
nous route. Another application of intranasal drug delivery system in therapeutics is their use
in development of vaccines. Immunity is achieved by the administration of mucosal antigen.
Currently, the first intranasal vaccine has been marketed [158]. Among the possible delivery
systems, the use of nano based carriers hold a great promise to protect the biomolecules,
promote nanocarrier interaction with mucosae and to direct antigen to the lymphoid tissues.
Therefore the use of nanoemulsions in intranasal drug delivery system is set to bring about
significant results in targeting drugs to the brain in treatment of diseases related to the central
nervous system [159]. Bhanushali et al developed intranasal nanoemulsion and gel formula‐
tions for rizatriptan benzoate for prolonged action [160]. Various mucoadhesive agents were
tried out to form thermo-triggered mucoadhesive nanoemulsions. Mucoadhesive gel formu‐
lations of rizatriptan were prepared using different ratios of HPMC and Carbopol 980.
Comparative evaluation of intranasal nanoemulsions and intranasal mucoadhesive gels
indicated that greater brain-targeting could be achieved with nanoemulsions. Other drugs
which have been formulated for nasal delivery are insulin and testosterone [161].
6.12. Nanoemulsions and parenteral drug delivery
This is one of the most common and effective routes of drug administration usually adopted
for actives with low bioavailability and narrow therapeutic index. Their capacity to dissolve
large quantities of hydrophobics, together with their mutual compatibility and ability to
protect the drugs from hydrolysis and enzymatic degradation make nanoemulsions ideal
vehicles for the purpose of parenteral transport. Further, the frequency and dosage of injections
can be reduced throughout the drug therapy period as these emulsions guarantee the release
of drugs in a sustained and controlled mode over long periods of time. Additionally, the lack
of flocculation, sedimentation and creaming, combined with a large surface area and free
energy, offer obvious advantages over emulsions of larger particle size, for this route of
administration [69]. Their very large interfacial area positively influences the drug transport
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and their delivery, along with targeting them to specific sites. Major clinical and pre-clinical
trials have hence been carried out with parenteral nanoemulsion based carriers. The advances
in these novel drug delivery systems have been reviewed by Patel and Patel [162]. Nanoe‐
mulsions loaded with thalidomide have been synthesized where a dose as low as 25 mg leads
to plasma concentrations which can be therapeutic [163]. However, a significant decrease in
the drug content of the nanoemulsion was observed at 0.01% drug formulation after two
months storage which could be overcome by the addition of polysorbate 80. Chlorambucil, a
lipophilic anticancer agent has been used against breast and ovarian cancer. Its pharmacoki‐
netics and anticancer activity has been studied by loading it in parenteral emulsions prepared
by high energy ultrasonication method. Treatment of colon adenocarcinoma in the mouse with
this nanoemulsion leads to higher tumor suppression rate compared to plain drug solution
treatment, concluding that the drug loaded emulsion could be an effective carrier for its
delivery in cancer treatment [164]. Carbamazepine, a widely used anticonvulsant drug had no
parenteral treatment available for patients due to its poor water solubility. Kelmann et al. have
developed a nanoemulsion for its intravenous delivery, which showed favorable in vitro
release kinetics [165]. Parenteral nanoemulsion formulations of the following drugs have been
documented as well: diazepam, propofol, dexamethasone, etomidate, flurbiprofen and
prostaglandin E1 [166].
The high lipophilicity of diazepam (an anxiolytic and sedative) makes the use of solvents (such
as propylene glycol phenyl carbinol and ethanol) for the dissolution of the drug in conventional
aqueous preparations (Valium® and Stesolid®) necessary, leading to pain and thrombophlebitis
on the patient during the injection. The development of a nanoemulsion, commercially
available under the name of Diazemuls® (Kabi-Pharmacia) allows for the reduction of these
adverse effects, keeping stages of distribution and elimination similar to Valium®. However,
higher doses of Diazemuls® are necessary to obtain the same effect as Valium® since this leads
to higher free fraction of plasma diazepam [167,168].
The solution for intravenous administration of etomidate (hypnotic short) due to stability
problems, its composition contains 35 % propylene glycol (Hypnomidate®) [169,170]. Due to
the presence of high osmolarity of the solvent, the administration is associated with various
adverse effects such as hemolysis, thrombosis, thrombophlebitis and pain at the site of
application [171,172]. A nanoemulsion containing 2 mg/ml Lipofundin® etomidate in medium
chain triglyceride named Lipuro-etomidate® (B. Braun) was developed [173]. The emulsion
allowed the reduction of the hemolytic and venous sequelae, besides the pain at the time of
application [169-171].
The pharmacokinetics and pharmacodynamics of propofol (anesthetic) are complex. It has an
initial rapid distribution of about 2-3 minutes, with high variability between patients and
reduced concentrations to subtherapeutic levels within minutes. However, due to its high
lipophilicity, it has a high volume of distribution and its complete elimination from the body
can take days [174]. Due to the occurrence of anaphylactic effects associated with Cremophor
EL, present in the original formulation of propofol nanoemulsion as vehicle for this drug-
containing composition in soybean oil, glycerol, egg yolk lecithin and disodium edentate, this
vehicle helped to reduce the volume of distribution of the drug, accelerating their processes of
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clearance by the responsible agencies. This formulation also allowed the use of minimal effective
dose need to produce the needed therapeutic effect, allowing a rapid onset and recovery from
anesthesia, when compared to a non-lipid (ethanol) solution, thereby generating greater security
administration, due to the lower continuous accumulation of the drug, and eliminating the need
for constant adjustment of the dose. This product was approved in 1989 in the United States,
under the name of Diprivan® 1 or 2 % (AstraZeneca / APP Pharmaceuticals) [175]. In Brazil, the
product is available as Lipuro 1% (B. Braun) and Diprivan® 1 and 2% (AstraZeneca), besides
the generic 1% (Eurofarma Labs.) [176]. The various generic formulations currently available
are constituted by an additional factor of variability in response between individuals in the
induction of anesthesia, apart from the pharmacokinetic characteristics of the drug itself [174]
and the differences in lipoprotein profile of each patient, due to the high binding of propofol to
low density lipoprotein and albumin [177]. Due to related pain at the injection site and increased
triglyceride levels after administration for long periods, some changes in the formulation of
Diprivan® adverse effects have been proposed, including some already being marketed as
Propofol® Lipuro (B. Braun) as oil core which contains a mixture of oils [178]. The addition of
more oil  to the formulation allowed the reduction of pain on injection due to increased
incorporation of the drug in the oily core and the lower amount of free propofol phase the
external aqueous emulsion [171,177-180]. Alternative formulations have been developed, for
example, the incorporation of higher concentrations of propofol (6 %) in the nanoemulsion
[180-182], or the development of a propofol prodrug in solution (Aquavan®) [183].
Furthermore, despite the excellent anti-inflammatory activity of dexamethasone, the clinical
use of corticosteroids is limited by numerous side effects [184,185]. To circumvent these
drawbacks, lipophilic prodrugs in the body that are gradually hydrolyzed to the active
metabolite can be used (thus presenting prolonged anti-inflammatory effect). The advantage
is the use of lower doses than those used in conventional water soluble form (dexamethasone
phosphate), reducing the risks of adverse effects. Considering that nanoemulsions are picked
up by inflammatory cells of the mononuclear phagocytic system, nanoemulsions were used
as a vehicle for lipophilic prodrug of dexamethasone (palmitate), which is commercially
available as Limethason® (Green Cross Co./Mitsubishi Tanabe Pharma Co.). Limethason®
showed excellent results in the treatment of rheumatoid arthritis, West syndrome, inflamma‐
tory diseases and other autoimmune diseases. While the solution of dexamethasone phosphate
is rapidly distributed in water-rich tissues, such as muscles, the nanoemulsion is accumulated
mainly in tissues inflamed organs such as liver and spleen. The biodistribution profile is
different even if the elimination pattern is similar between the two. Limethason® removes over
80 % of the phagocytic activity of macrophages at a concentration of 0.03 mg/mL [185].
Flurbiprofen (non-steroidal anti-inflammatory oral use), a lipophilic drug, is used to treat
rheumatoid arthritis and other inflammatory diseases associated or not with cancer [186]. The
non-availability of oral and/or various gastrointestinal effects caused by this drug often require
the use of parenteral route. Considering the severe local irritation caused by the sodium salt
of flurbiprofen, it was developed as a prodrug of flurbiprofen (cefuroxime) and because of the
lipophilicity of the latter especially in soybean oil, it was incorporated in nanoemulsions for
parenteral use (Ropion®, Kaken Pharmaceuticals Co., Lipfen®, GreenCross Co.), and is com‐
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mercially available in the Japanese market since 1992. Administration of Ropion® resulted in
an increase in area under the concentration-time curve and reduced clearance when compared
to the solution. The incorporation of the drug into nanoemulsions containing unesterified ethyl
oleate, lecithin and modified egg yolk led to a lower drug accumulation in organs such as the
liver and spleen due to the lower uptake by the mononuclear phagocyte system [166].
Prostaglandin E1, which is synthesized in several places of the body, is responsible for various
physiological effects such as vasodilatation, lowering of blood pressure, angiogenesis and
inhibition of platelet aggregation [187,188]. When administered for the treatment of various
diseases, it has a short half-life; high doses are needed, leading to numerous adverse effects such
as hypotension, diarrhea, local irritation and pain [187]. In this context, nanoemulsions were
made commercially available in 1975, PGE1 complexed to cyclodextrins and, in 1985, prostaglan‐
din E1 incorporated in lipid nanoemulsions (Liple®, Mitsubishi Tanabe Pharma Corporation,
Palux®,  Taisho Pharmaceutical) [189].  Lipid formulations are used to treat cardiovascular
diseases because they accumulate in the walls of injured vessels, transporting the drug to the
site of vascular injury and to protect it from rapid inactivation by the lungs [187-190].
6.13. Nanoemulsions and pulmonary drug delivery
The lung is an attractive target for drug delivery due to noninvasive administration via
inhalation aerosols, avoidance of first-pass metabolism, direct delivery to the site of action for
the treatment of respiratory diseases, and the availability of a huge surface area for local drug
action and systemic absorption of drug. Colloidal carriers (ie, nanocarrier systems) in pulmona‐
ry drug delivery offer many advantages such as the potential to achieve relatively uniform
distribution of drug dose among the alveoli, achievement of improved solubility of the drug
from its own aqueous solubility, a sustained drug release which consequently reduces dosing
frequency, improves patient compliance, decreases incidence of side effects, and the potential
of drug internalization by cells [191]. Until now, the submicron emulsion system has not yet
been fully exploited for pulmonary drug delivery and very little has been published in this area
[191]. Bivas-Benita et al. reported that cationic submicron emulsions are promising carriers for
deoxyribonucleic acid vaccines to the lung since they are able to transfect pulmonary epithe‐
lial cells, which possibly induce cross priming of antigen-presenting cells and directly acti‐
vate dendritic cells, resulting in stimulation of antigen-specific T-cells [192]. Therefore the
nebulization of submicron emulsions will be a new and upcoming research area. However,
extensive studies are required for the successful formulation of inhalable submicron emul‐
sions due to possible adverse effects of surfactants and oils on lung alveoli function (adverse
interactions with lung surfactant). A novel pressurized aerosol system has been devised for the
pulmonary delivery of salbutamol using lecithin-stabilized microemulsions formulated in
trichlorotrifluoroethane [193].
6.14. Nanoemulsions as gene delivery vector
Emulsion systems have been introduced as alternative gene transfer vectors to liposomes [194].
Other emulsion studies for gene delivery (non-pulmonary route) have shown that binding of
the emulsion/DNA complex was stronger than liposomal carriers [195]. This stable emulsion
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system delivered genes more efficiently than liposomes [196]. Silva et al evaluated factors that
influence DNA compaction in cationic lipid nanoemulsions [cationic nanoemulsions contain‐
ing stearylamine (a cationic lipid that presents a primary amine group when in solution, is able
to compact genetic material by electrostatic interactions, and in dispersed systems such as
nanoemulsions this lipid anchors on the oil/water interface conferring a positive charge to
them)] [197]. The influence of the stearylamine incorporation phase (water or oil), time of
complexation, and different incubation temperatures were studied. The complexation rate was
assessed by electrophoresis migration on agarose gel 0.7%, and nanoemulsion and lipoplex
characterization was done by dynamic light scattering (DLS). The results demonstrate that the
best DNA compaction process occurs after 120 min of complexation, at low temperature (4 ±
1 °C), and after incorporation of the cationic lipid into the aqueous phase. Although the zeta
potential of lipoplexes was lower than the results found for basic nanoemulsions, the granul‐
ometry did not change. Moreover, it was demonstrated that lipoplexes are suitable vehicles
for gene delivery.
7. Nanoemulsions for phytopharmaceuticals
Recently, considerable attention has been focused on the development of novel drug delivery
systems for herbal drugs [198]. However some limitations of plant bioactives like instability
in highly acidic pH and liver metabolism led to drug levels below therapeutic concentration
in the blood resulting in less or no therapeutic effect [199]. Hence, encapsulation of plant
extracts or its bioactives would minimize their degradation or presystemic metabolism, and
serious side effects due to accumulation of drugs to the non-targeted areas and improves the
ease of administration in the pediatric and geriatric patients [200]. Lipid nanoemulsions
containing oil from medicinal plants or hydrophobic drugs have been shown to improve drug
solubility, reduce side effects of various potent drugs, increase the bioavailability of drugs,
and to prolong the pharmacological effects in comparison to conventional formulations such
as conventional emulsions [201]. Formulation of nanoemulsions containing phytoactives have
been reported.
The effect of nanoemulsion on intestinal absorption of colchicine was demonstrated in vivo.
Colchicine nanoemulsion was prepared with isopropyl myristate, eugenol, Tween 80, ethanol
and water, with eugenol being the oil phase in the formulation. Result obtained indicated that
the intestinal absorption of colchicine was significantly enhanced by the nanoemulsion
formulation [202]. Genistein has been shown to possess anticancer activities in different
experimental systems, yet the same effects could not be translated in the clinical setting due
to its poor bioavailability. Researcher have tried various nano approaches including incorpo‐
ration of genistein into topical nanoemulsion formulations composed of egg lecithin, medium
chain triglycerides or octyldodecanol and water by spontaneous emulsification with improved
activity [203]. Oil in water nanoemulsion formulation has also demonstrated increased anti-
inflammatory activity of curcumin [204].
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8. Future perspectives
Nanoemulsions are proposed for numerous applications in pharmacy as drug delivery
systems because of their capacity to solubilize non-polar active compounds. Future perspec‐
tives of nanoemulsion are very promising in different fields of therapeutics or application in
development of cosmetics for hair or skin. One of the versatile applications of nanoemulsions
is in the area of drug delivery where they act as efficient carriers for bioactives, facilitating
administration by various routes. The advantages and applications of nanoemulsions for oral
drug delivery are numerous, where the droplet size is related to their absorption in the
gastrointestinal tract. Due to the renewed interest in herbal drug formulation, nanoemulsion
may be the ideal delivery platform for these difficult-to-formulate phytopharmaceuticals. The
prospects of nanoemulsions lie in the ingenuity of formulation experts to utilize the advantages
of nanoemulsion carriers in overcoming peculiar problems of drug delivery such as absorp‐
tion, permeation and stability of both orthodox and herbal drugs.
9. Conclusion
Nanoemulsions offer several advantages for the delivery of drugs and are thus receiving
increasing attention as drug carriers for improving the delivery of active pharmaceutical
ingredients. They are applicable for almost all routes of delivery and therefore hold promise
for different fields, be it cosmetics, therapeutics or biotechnology. This new technology could
be developed to overcome the poor absorption of some phytopharmaceuticals and poor
miscibility of these compounds with the lipid contents of cell membrane linings.
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